Adamis Pharmaceuticals Announces $3M Registered Direct Offering With A Single, Healthcare-Focused Institutional Investor
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose,
Puma Biotechnology Announces Publication Of Phase II Clinical Trial Of Alisertib In JAMA Oncology
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that the results of the Phase II TBCRC041 randomized clinical trial of alisertib alone or in combination with fulvestrant in patients with
Reported Late Monday March 13, Natura Reports Q4 Results; Consolidated Net Revenue Of R$10.39B
Strong growth by Natura &Co Latam and Aesop, which made a successful entry into China in Q4; further improvement in Avon fundamentals and growth in the Beauty category
SÃO
Reported Late Monday March 13, Rumble Becomes Exclusive Streaming Home Of Power Slap Seasons 2 And 3
Rumble and Power Slap reach agreement in principle for exclusive global rights to Seasons 2 and 3 of the popular new slap fighting league.
Agreement also includes additional Power Slap live events.
Reported Late Monday March 13, Inter&Co, Inc Reports Q4 And FY22 Financial Results; Says Total Gross Revenues Strong Year Reaching R$6B, Up 90% YoY. Our Revenues Continue To Be Highly Diversified, With Fees Comprising 34% Of Net Revenues
https://api.mziq.com/mzfilemanager/v2/d/b4dc0b14-a83a-40a9-9545-d9e4f18ed7af/11f0f3a8-5620-9520-30f1-09128618b3c5?origin=1
2022 Highlights:
Client Growth: We added 8.3 million net new clients during the year,
Reported Late Monday March 13, Everest Medicines Announces Partner Calliditas Therapeutics Reports Topline Results From Phase 3 NefIgArd Trial Evaluating Nefecon In IgA Nephropathy; Trial Primary Endpoint Was Met With Nefecon
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced today that its partner Calliditas Therapeutics AB (NASDAQ:CALT, Nasdaq Stockholm: CALTX)))) ("Calliditas") reported
Reported Late Monday March 13, Haynes International Announces $71,484 Restricted Stock Award Agreement In The Amount Of 1,400 Shares Of Common Stock To The Grantee
The Company wishes to provide incentives to recognize and reward the Grantee, whose performance, contributions and skills will be critical to the Company's success, by aligning his/her interests more closely with
Reported Late Monday March 13, Reunion Neuroscience Files Lawsuit Against Mindset Pharma Alleging That Mindset Knowingly Copied Reunion’s RE104 Compound And Misleadingly Presented That Exact Composition To The Patent Office As Mindset’s Invention
Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion"
Reported Late Monday March 13, Innoviva Announces FDA Advisory Committee Meeting To Review Sulbactam-Durlobactam An Investigational Targeted Antibiotic On April 17, 2023
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that the U.S. Food and Drug Administration's (FDA)